In this context, it is worth noting the study conducted by Ben Abdelali et al., who revealed that the favorable prognosis of Notch1/FBXW mutations in adult T‐ALL was found in more intense, pediatric-inspired GRAALL chemotherapy protocols but not in the less-intense LALA-94 study [32]. The gene discussed is NOTCH1; the disease is acute lymphoblastic leukemia.